IP Library Granted Patent US 8,512,994
Granted Patent B2
US 8,512,994 · App. 13/301,204 · Granted Aug 20, 2013

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

Inventors: Pierre Charneau (Paris, FR); Veronique Zennou (Paris, FR); Francoise Pflumio (Vitry/Siene, FR); Aride Sirven (Paris, FR); Anne Dubart (Choisy le Roi, FR)
Assignees: Institut Pasteur; Institut National de la Santé et de la Recherche Médicale; Centre National de la Recherche Scientifique
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,512,994
App. No.
13/301,204
Granted
Aug 20, 2013
Kind
B2
Abstract

The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.

Claims (28)

1. A method for producing a lentiviral gene transfer vector that promotes nuclear import of a gene of interest comprising generating a gene transfer vector comprising:

(a) at least one copy of the cPPT and CTS cis-acting regions of a retrovirus, wherein said cPPT and CTS regions induce a three-stranded DNA structure,

(b) a gene of interest,

(c) an HIV-1 LTR that is deleted for the promoter and the enhancer of U3, and

(d) a cis-acting lentiviral encapsidation sequence.

2. The method of claim 1 , wherein the cPPT and CTS regions are lentiviral cPPT and CTS regions.

3. The method of claim 2 , wherein the cPPT and CTS regions are human immunodeficiency virus (HIV) cPPT and CTS regions.

4. The method of claim 2 , wherein the cPPT and CTS regions are HIV-1 cPPT and CTS regions.

5. The method of claim 2 , wherein the cPPT and CTS regions are HIV-2 cPPT and CTS regions.

6. The method of claim 2 , wherein the cPPT and CTS regions are VISNA, EIAV, FIV, or CAEV cPPT and CTS regions.

7. A method for producing a lentiviral gene transfer vector that promotes nuclear import of a gene of interest comprising:

(a) inserting into the gene transfer vector at least one copy of the cPPT and CTS cis-acting regions of a retrovirus, wherein said cPPT and CTS regions induce a three-stranded DNA structure,

(b) inserting into the gene transfer vector a gene of interest,

(c) inserting into the gene transfer vector an HIV-1 LTR that is deleted for the promoter and the enhancer of U3,

wherein the gene transfer vector comprises a cis-acting lentiviral encapsidation sequence.

8. The method of claim 7 , wherein the cPPT and CTS regions are lentiviral cPPT and CTS regions.

9. The method of claim 8 , wherein the cPPT and CTS regions are human immunodeficiency virus (HIV) cPPT and CTS regions.

10. The method of claim 8 , wherein the cPPT and CTS regions are HIV-1 cPPT and CTS regions.

11. The method of claim 8 , wherein the cPPT and CTS regions are HIV-2 cPPT and CTS regions.

12. The method of claim 8 , wherein the cPPT and CTS regions are VISNA, EIAV, FIV, or CAEV cPPT and CTS regions.

13. A method for producing a lentiviral gene transfer vector that promotes nuclear import of a gene of interest comprising inserting into a gene transfer vector comprising a cis-acting lentiviral encapsidation sequence and an HIV-1 LTR that is deleted for the promoter and the enhancer of U3:

(a) at least one copy of the cPPT and CTS cis-acting regions of a retrovirus, wherein said cPPT and CTS regions induce a three-stranded DNA structure; and

(b) a gene of interest.

14. The method of claim 13 , wherein the cPPT and CTS regions are lentiviral cPPT and CTS regions.

15. The method of claim 14 , wherein the cPPT and CTS regions are human immunodeficiency virus (HIV) cPPT and CTS regions.

16. The method of claim 14 , wherein the cPPT and CTS regions are HIV-1 cPPT and CTS regions.

17. The method of claim 14 , wherein the cPPT and CTS regions are HIV-2 cPPT and CTS regions.

18. The method of claim 14 , wherein the cPPT and CTS regions are VISNA, EIAV, FIV, or CAEV cPPT and CTS regions.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2012
From: INSTITUT PASTEUR; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
To: INSTITUT PASTEUR; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Reel/Frame 028359/0751 →
Continuity (4)
Continuation 11291390 · Dec 1, 2005
Continuation 09685343 · Oct 11, 2000
Provisional Application 60158387 · Oct 12, 1999
Related Publication 20120122204A1 · May 17, 2012